Therefore, we speculate that the mechanisms underlying the link between decreased MIP-1α and MIP-1β levels and the risk of developing NPC are related to the dysfunction of anti-EBV immunity and anti-tumor immunity. The gene discussed is CCL4; the disease is nasopharyngeal carcinoma.